Thromboprophylaxis for Coagulopathy Related to Covid-19 in Pediatrics: A Narrative Review Publisher Pubmed



Sahrai H¹ ; Hemmatighavshough M¹ ; Shahrabi M² ; Jafarirouhi AH³ ; Solduzian M⁴
Source: Pediatric Drugs Published:2023

Abstract

In addition to harming the respiratory system, COVID-19 can affect multiple organs. Children may develop a specific complication of COVID-19 called multisystem inflammatory syndrome in children (MIS-C) which could influence the vascular system of children and cause multiple coagulopathies in the body. Information on the use of thromboprophylaxis in this condition was collected via the review of various articles. In general, different factors in immune system responses can trigger the initiation of thrombotic events. Studies have shown that starting anticoagulant prophylaxis, which contributes to decreased thrombotic events, is dependent on the patient's condition and D-dimer levels. However, further studies on pediatric populations are needed to establish the role of anticoagulants in children with this condition. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.